Clinical Trials · NCT01110707

A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Merck KGaA, Darmstadt, Germany
Enrollment
131
Start date
Jan 2005
Locations
1 site, Spain
Primary endpoint
Mean Number of Metaphase II (M-II) Oocytes Retrieved
View Gonadorelin compound reference